Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome. * Treatment of duodenal ulcers. * Treatment of gastric ulcers. ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. For maintenance of healing, 40 mg orally once daily may be continued. * **GERD (symptomatic relief):** 20 mg orally once daily. If symptoms are not controlled after 4 weeks, consider treatment for up to 4 more weeks. * **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks. * **Gastric Ulcers:** 40 mg orally once daily for up to 4 weeks. * **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is typically 40 mg orally twice daily. Doses may be titrated up to 240 mg per day, administered as 40 mg three times daily. Doses exceeding 80 mg daily should be divided and given twice daily. *Note: Intravenous formulations are available for patients unable to take oral medication.* ## Pediatric Dosing * **Erosive Esophagitis (age 5 to 16 years):** 20 mg orally once daily for up to 8 weeks. Dosing may be adjusted to 40 mg orally once daily if needed. * **GERD (age 5 to 16 years):** 20 mg orally once daily for up to 4 weeks for symptomatic relief. *Dosing for pediatric patients younger than 5 years is not established.* ## Dose Adjustments * **Hepatic Impairment:** Maximum dose of 40 mg once daily. * **Renal Impairment:** No dose adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. ## Adverse Effects Common: Headache, diarrhea, nausea, abdominal pain, dizziness. Less Common: Flatulence, dry mouth, fatigue, muscle pain, rash. ## Key Drug Interactions * **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternatives or co-administration with caution. * **Methotrexate:** PPIs can increase methotrexate levels, potentially leading to toxicity. Monitor methotrexate levels. * **Certain Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease absorption of these drugs due to increased gastric pH. * **Drugs Dependent on Gastric pH for Absorption:** (e.g., ketoconazole, itraconazole, iron salts) - Pantoprazole may decrease their absorption. ## Monitoring * Symptom relief (heartburn, regurgitation). * For long-term use: Monitor for signs of vitamin B12 deficiency (e.g., fatigue, neurological symptoms) and hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias), especially with prolonged therapy (over 1 year). * Bone mineral density monitoring may be considered in patients at risk for osteoporosis. ## Clinical Pearls * Administer oral pantoprazole at least 30 minutes before a meal. * Do not crush or chew delayed-release tablets or capsules; they should be swallowed whole. If a patient cannot swallow whole, they can be mixed with applesauce. * Long-term PPI use has been associated with an increased risk of Clostridium difficile infection, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia. * Consider the potential for drug interactions, especially with clopidogrel and methotrexate. *** **Disclaimer:** This information is intended for healthcare professionals and does not replace a thorough review of the official prescribing information. Always consult the current product monograph and relevant guidelines for complete and up-to-date information before prescribing.